Advanced HIV infection treated with zidovudine monotherapy: Lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments

Annals of Pharmacotherapy

Volumn 31, Issue 12, 1997, Pages 1447-1453

  Messori, Andrea ^a   Becagli, Paola ^a   Berto, Valeria ^b   Trippoli, Sabrina ^a   Font, Maria ^c   Tosolini, Francesca ^c   Venturini, Francesca ^c   Martini, Nello ^d  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Osp Polic Borgo Roma   (Italy)

^c Policlinico Careggi Hospital ^*

^d UO Gastroenterologia ed Endoscopia Digestiva   (Italy)

Author keywords

Cost effectiveness; Human immunodeficiency virus; Saquinavir; Zalcitabine; Zidovudine

Indexed keywords

SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ARTICLE; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFESPAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REFERENCE VALUE; SURVIVAL;

EID: 0031437657     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703101201     Document Type: Article

References (30)

1. Gelber RD, Goldhirsch A, Cavalli F. Quality-of-life-adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 1991; 114:621-8.
2. Gelber RD, Lenderking WR, Cotton DJ, Cole BF, Fischi MA, Goldhirsch A, et al. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. Ann Intern Med 1992;116:961-6.
3. Gelber RD, Goldhirsch A, Cole BF, Wieand HS, Schroeder G, Krook JE. A quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst 1996;88:1039-45.
4. Gelber RD, Cole BF, Goldhirsch A, Rose C, Fisher B, Osborne CK, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone in post-menopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996;347:1066-71.
5. Cole BF, Gelber RD, Kirkwood JM, Goldhirsch A, Barylak E, Borden E. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1996;14:2666-73.
6. Messori A. Survival curve fitting using the Gompertz function: a methodology for conducting cost-effectiveness analyses on mortality data. Comput Methods Programs Biomed 1997;52:157-64.
7. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
8. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996;51:111-6 (erratum 1996;51:427).
9. Messori A, Bonistalli L, Costantini M, Trallori G, Tendi E. Cost-effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. J Clin Gastroenterol 1996;23:269-74.
10. Messori A, Becagli P, Trippoli S, Tendi E. A retrospective cost-effectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma. Eur J Cancer 1997;33:1373-9.
11. Messori A, Trippoli S, Becagli P, Tendi E. Pharmacoeconomic profile of paclitaxel as first-line treatment for patients with advanced ovarian cancer: a lifetime cost-effectiveness analysis. Cancer 1996;78:2366-73.
12. Messori A, Bonistalli L, Costantini M, Alterini R. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997;19:275-81.
13. Messori A, Cecchi M, Becagli P, Trippoli S. Pharmacoeconomic profile of paclitaxel as first-line treatment for patients with advanced ovarian cancer: a lifetime cost-effectiveness analysis (letter). Cancer 1997;79: 2264-5.
14. Oddone EZ, Cowper P, Hamilton GD, Matchar DB, Hartigan P, Samsa G, et al. Cost effectiveness analysis of early zidovudine treatment of HIV infected patients. BMJ 1993;307:1322-5.
15. Freeberg KA, Tosteson AN, Cotton DJ, Goldman L. Optimal management strategies for HIV-infected patients who present with cough or disponea: a cost-effectiveness analysis. J Gen Intern Med 1992;7:261-72.
16. Paltiel AD, Kaplan EH. Modeling zidovudine therapy: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991;4:795-804.
17. Schulman KA, Lynn LA, Glick HA, Eisenberg JM. Cost-effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus infection. Ann Intern Med 1991;114:798-802.
18. Doran CM. New approaches to using antiretroviral therapy for the management of HIV infection. Ann Pharmacother 1997;31:228-36.
19. Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996;335:1099-106.
20. Collier AC, Coombs RW, Schoenfeld DA, Bassett RL, Timpone J, Baruch A, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996;334: 1011-7.
21. Hurley FS, Kaldor JM, Gardiner S, Carlin JB, Assuncao RM, Evans DB. Lifetime cost of human immunodeficiency virus-related health-care. J AIDS Hum Retrovirol 1996;12:371-8.
22. Robinson R. Cost-effectiveness analysis. BMJ 1993;307:793-5.
23. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337: 725-33.
24. 1996 Red book. Montvale, NJ: Medical Economics Data, 1996.
25. Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, et al. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N Engl J Med 1994;330:738-43.
26. Vanhems P, Toma E, Pineault R. Quality of life assessment and HIV infection: a review. Eur J Epidemiol 1996;12:221-8.
27. Cella DF, McCain NL, Peterman AH, Mo F, Wolen D. Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Qual Life Res 1996;5: 450-63.
28. Cohen SR, Hassan SA, Lapointe BJ, Mount BM. Quality of life in HIV disease as measured by the McGill quality of life questionnaire. AIDS 1996;10:1421-7.
29. Owens DK, Cardinalli AB, Nease RF. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. Qual Life Res 1997;6:77-86.
30. Coyle D. Statistical analysis in pharmacoeconomic studies - a review of current issues and standards. PharmacoEconomics 1996;6:506-16.